India’s Contract Development and Manufacturing Organization (CDMO) market is on the brink of a substantial transformation. With current valuations at approximately USD 7 billion, forecasts suggest that this sector will double to nearly USD 14 billion by 2028. This remarkable growth presents significant implications not only for the Indian pharmaceutical landscape but also for global supply chains and healthcare delivery.
Key Drivers of Growth
The anticipated expansion of India’s CDMO market is propelled by several influential factors:
1. Strong Position in Active Pharmaceutical Ingredients (API):
India has established a robust reputation as a leading manufacturer of APIs and generic drugs. This advantage positions it favourably against other major producers like China, particularly as pharmaceutical companies seek to secure their supply chains away from geopolitical tensions.
2. Cost Effectiveness:
Indian CDMOs offer services that are approximately 20% cheaper than their counterparts in China, making them an attractive option for multinational pharmaceutical firms aiming to optimize production costs while maintaining quality.
3. Surge in Requests for Proposals (RFPs):
In 2024, Indian CDMOs experienced an unprecedented 50% year-on-year increase in RFPs, indicating heightened interest from global companies to explore partnerships in drug development and manufacturing.
4. Diversifying Supply Chains:
Global pharmaceutical companies are actively diversifying their supply chains amid supply chain disruptions and rising costs of production. India’s capabilities and resources allow foreign firms to mitigate risks associated with concentrated manufacturing bases.
Emerging Trends in Biopharmaceuticals
The CDMO market is evolving in tandem with broader advancements in biopharmaceuticals. Key emerging drug modalities—such as Cell and Gene Therapy, Antibody-Drug Conjugates (ADCs), and Nucleic Acid Therapeutics—are gaining traction, with projected growth rates of 45%, 25%, and 36% CAGR, respectively. These innovative therapies often require specialized manufacturing processes, thereby increasing the demand for advanced CDMO services.
The Broader Asia-Pacific Healthcare Landscape
As the Asia-Pacific healthcare sector continues to experience rapid growth, with projections to hit USD 5 trillion by 2030, the role of Indian CDMOs will be vital. Rising income levels and a steadily increasing number of high-income households are pushing demand for high-quality healthcare products and services.
Moreover, foreign direct investment (FDI) in the healthcare sector has doubled since 2008, marking a significant shift towards enhancing healthcare infrastructure and services throughout Asia. With pharmaceuticals set to grow at a 9% CAGR over the next five years and MedTech expanding at 8% CAGR, opportunities for CDMOs in India stand to amplify considerably.
Conclusion
India’s CDMO market is poised for unprecedented growth as it supports the expanding global healthcare needs. By leveraging its established leadership in API manufacturing, cost advantages, and commitment to innovation, India can solidify its status as a critical player in the global pharmaceutical landscape. As global supply chains continue to evolve, Indian CDMOs are well-positioned to deliver the scalable and cost-effective solutions necessary to support the next generation of healthcare advancements.
-NSH Digidesk
